- UroGen Pharma Ltd. (URGN, Financial) reports nearly four-year duration of response for certain patients treated with JELMYTO.
- OLYMPUS study finds median response duration of 47.8 months in low-grade upper tract urothelial cancer patients.
- JELMYTO continues to show promising long-term efficacy in both new-onset and recurrent cancer cases.
UroGen Pharma Ltd. (URGN), a biotech firm focused on urothelial and specialty cancer treatments, recently shared compelling findings at the American Urological Association's 2025 Annual Meeting in Las Vegas. The long-term follow-up study of JELMYTO® (mitomycin), an FDA-approved treatment for low-grade upper tract urothelial cancer (LG-UTUC), reveals a median duration of response of 47.8 months among patients who achieved a complete response in the OLYMPUS trial.
Dr. Brian Hu from Loma Linda University Health emphasized the significance of these results, noting that JELMYTO provides durable responses and reduces recurrence rates for both new-onset and recurrent LG-UTUC patients. The trial included 41 patients, evenly distributed between new-onset (21) and recurrent (20) cases, with no notable difference in outcomes between the groups. The median follow-up period for these patients was 28.1 months.
Further insights from the OLYMPUS Phase 3 trial demonstrate that 20 patients entered long-term follow-up, with a median follow-up of 53.3 months. The median duration of response was not estimable due to a low event rate, pointing towards JELMYTO's potential for sustained therapeutic benefits.
UroGen continues to expand its understanding of JELMYTO through the uTRACT Registry, which aims to collect real-world usage data. As of April 2025, the registry has enrolled 251 patients across 22 sites. UroGen's ongoing efforts underscore the promise of JELMYTO in improving treatment outcomes for patients with LG-UTUC.
